Fact-checked by Grok 2 weeks ago

Pernicious anemia

Pernicious anemia is a chronic autoimmune disorder characterized by a deficiency in red blood cells due to impaired absorption of vitamin B12 in the intestines, primarily caused by the destruction of gastric parietal cells that produce intrinsic factor, a protein essential for B12 uptake.^[1] This condition, also known as Biermer's disease, results in megaloblastic anemia, where bone marrow produces oversized, immature red blood cells that function poorly, leading to fatigue, weakness, and pallor as hallmark symptoms.^[2] If untreated, it can progress to severe neurological damage, including numbness, cognitive impairment, and irreversible nerve degeneration, due to disrupted DNA synthesis and myelin sheath formation from B12 shortage.^[3] The etiology of pernicious anemia is predominantly autoimmune, with antibodies targeting intrinsic factor or parietal cells, often in the context of atrophic gastritis, and it affects approximately 1-2% of older adults, particularly those of Northern European descent, with a peak incidence around age 60.^[2] Associated autoimmune conditions, such as type 1 diabetes, thyroiditis, or vitiligo, and family history increase risk. Other causes of impaired B12 absorption include prior gastric surgery that removes intrinsic factor-producing cells.^[1] Symptoms typically emerge gradually and include not only hematological signs like shortness of breath, dizziness, and irregular heartbeats but also gastrointestinal issues such as glossitis (inflamed tongue) and, in advanced cases, psychiatric manifestations like depression or irritability.^[3] Diagnosis involves blood tests revealing low B12 levels, elevated methylmalonic acid and homocysteine, macrocytic red blood cells on complete blood count, and confirmatory anti-intrinsic factor antibodies, which are highly specific though not always present.^[2] Endoscopy may identify atrophic gastritis, and Schilling tests, though less common now, historically assessed B12 absorption.^[1] Treatment follows guidelines such as the 2024 NICE recommendations, requiring lifelong vitamin B12 replacement, typically via intramuscular injections of 1,000 mcg weekly initially then monthly, or high-dose oral supplements (1,000-2,000 mcg daily) for those with some absorption capacity, effectively reversing hematological symptoms within weeks but potentially leaving residual neurological deficits if delayed beyond six months.^[2]^[4] With prompt intervention, prognosis is excellent, though patients face elevated risks of gastric cancer and osteoporosis, necessitating regular monitoring.^[1]

Clinical Features

Signs and Symptoms

Pernicious anemia typically presents with a gradual onset of symptoms due to chronic vitamin B12 deficiency, often developing insidiously over months to years. Common early manifestations include profound fatigue and generalized weakness, which may significantly impair daily activities. Patients frequently report pallor of the skin and mucous membranes, shortness of breath on exertion, dizziness or lightheadedness, and loss of appetite leading to unintended weight loss. These symptoms arise from reduced oxygen-carrying capacity of the blood secondary to megaloblastic anemia.^[2]^[3]^[5] Neurological symptoms can emerge early or predominate in some cases, reflecting demyelination in the peripheral and central nervous systems. Individuals may experience numbness or tingling (paresthesias) in the hands and feet, progressing to difficulty walking with unsteady gait or ataxia. Additional features include memory loss, cognitive impairment, confusion, and mood changes such as irritability or depression. In advanced stages, peripheral neuropathy may cause symmetric sensory loss in the extremities, with decreased vibration and position sense.^[2]^[3]^[5] Cardiovascular signs often accompany severe anemia, including tachycardia and palpitations due to compensatory increased cardiac output. In extreme cases, this can lead to heart failure with symptoms like dyspnea at rest and peripheral edema. Gastrointestinal involvement manifests as glossitis—a sore, smooth, beefy-red tongue—along with nausea, dyspepsia, or diarrhea.^[2]^[3] Physical examination may reveal a characteristic lemon-yellow tint to the skin, particularly in individuals of European ancestry, resulting from pallor combined with mild jaundice due to ineffective erythropoiesis and hemolysis. Hyperpigmentation of the skin, especially in creases or pressure areas, can also occur, more commonly in darker skin tones. Other findings include dry skin, cheilosis, and splenomegaly in some patients.^[2]^[3]

Complications

Untreated or advanced pernicious anemia can lead to severe neurological complications due to prolonged vitamin B12 deficiency. Subacute combined degeneration of the spinal cord is a hallmark manifestation, characterized by demyelination and axonal damage primarily affecting the dorsal and lateral columns, resulting in symmetric leg weakness, ataxia, paresthesia, loss of vibration and proprioception sense, spastic paraparesis, and gait disturbances.^[6] These symptoms often progress to irreversible deficits, such as permanent sensory ataxia or paraparesis, if not addressed promptly, though up to 86% of cases show clinical improvement with early intervention.^[6] Peripheral neuropathy commonly presents as reduced sensitivity to touch, pinprick, and vibration, contributing to further motor and sensory impairments.^[2] Optic atrophy may cause visual disturbances, while cognitive decline resembling dementia, including reversible mental status changes and brain atrophy, arises from associated hyperhomocysteinemia.^[2]^[6] Hematological complications from severe megaloblastic anemia in pernicious anemia can be life-threatening. Profound anemia leads to ineffective erythropoiesis and significant reductions in erythrocytes, increasing the risk of high-output heart failure due to compensatory cardiac strain.^[2]^[7] Pernicious anemia elevates the risk of gastric carcinoma, particularly non-cardia gastric adenocarcinoma and carcinoid tumors, with an incidence of approximately 0.27% per person-year based on meta-analyses of over 22,000 patients.^[2]^[8] This risk persists even after vitamin B12 therapy, showing an 11-fold increase for gastric carcinoids among associated malignancies.^[2]^[9] Additionally, pernicious anemia is frequently linked to other autoimmune disorders, such as autoimmune thyroiditis, as part of polyglandular autoimmune syndromes, with higher co-occurrence rates observed in clinical cohorts.^[2]^[10] Rare complications include infertility, which manifests in both men and women due to ovulatory disruptions or implantation defects from B12 deficiency, often resolving post-treatment.^[11]^[12] Osteoporosis represents another concern, with pernicious anemia identified as an independent risk factor for bone loss and fractures, including persistent elevated hip fracture risk years after B12 supplementation.^[13]^[14] Hyperhomocysteinemia secondary to B12 deficiency heightens thrombosis risk, predisposing individuals to deep vein thrombosis, pulmonary embolism, cerebral venous thrombosis, and splanchnic vein events, sometimes as initial presentations.^[15]^[16]

Etiology

Primary Causes

Pernicious anemia primarily arises from a deficiency in intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells essential for vitamin B12 absorption, most commonly due to autoimmune mechanisms targeting these cells or IF itself.^[2] In the predominant autoimmune form, type I autoantibodies against IF block the binding of vitamin B12 to IF, preventing its uptake in the ileum, while type II autoantibodies prevent the attachment of the vitamin B12-IF complex to receptors in the ileum; type I antibodies are detected in 70% to 90% of affected patients.^[17] Concurrently, autoantibodies against the parietal cell's H+/K+-ATPase enzyme (type II in broader classification) lead to progressive destruction of these cells, resulting in atrophic gastritis and diminished IF production.^[2] The autoimmune process involves T-cell mediated inflammation, where CD4+ T cells, particularly Th1 subsets, recognize autoantigens on parietal cells and orchestrate their apoptosis through cytokine release.^[18] Pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), secreted by activated autoreactive T cells, amplify the inflammatory cascade, exacerbate mucosal atrophy, and contribute to the loss of parietal cell mass in the gastric corpus and fundus.^[19] This chronic immune attack culminates in severe atrophic gastritis, hallmark of autoimmune pernicious anemia.^[20] Although autoimmune etiologies predominate, non-autoimmune causes can also impair IF production or function, leading to pernicious anemia-like presentations. Chronic Helicobacter pylori infection induces persistent gastritis that may progress to multifocal atrophic gastritis, damaging parietal cells and reducing IF secretion, particularly in susceptible individuals.^[21] Iatrogenic factors further contribute, such as total or partial gastrectomy, which removes the source of IF production, or ileal resection, which disrupts the terminal ileum's IF-B12 receptor sites, both directly causing malabsorption.^[22] Genetic predispositions, such as variants in HLA genes, may heighten susceptibility to these autoimmune triggers but are not direct causes.^[2]

Risk Factors and Genetics

Pernicious anemia demonstrates a higher incidence in individuals over the age of 60, with symptoms typically emerging after 30 and average diagnosis around 60 years.^[1] It is more common in females, with varying female-to-male ratios observed across populations, often showing female predominance.^[2] The condition occurs at higher rates among people of Northern European or African ancestry.^[23] Environmental factors play a role in susceptibility, including a family history of autoimmune diseases, which elevates the risk through shared genetic and possibly environmental influences.^[24] Heavy alcohol consumption can impair vitamin B12 absorption, potentially exacerbating deficiency in at-risk individuals, though its specific contribution to autoimmune pernicious anemia remains indirect.^[23] Helicobacter pylori infection has been hypothesized to trigger autoimmunity in some cases, but its causative role is not definitively established.^[2] Genetic factors significantly contribute to predisposition, with genome-wide association studies identifying five key risk loci.^[25] These include associations with HLA-DR/DQ alleles, such as HLA-DRB115:01 (DR15), HLA-DQA101:02, and HLA-DQB1*06:02 (DQ6), which are linked to autoimmune susceptibility and increase the odds ratio for pernicious anemia by approximately 1.38 to 1.62.^[25] Other implicated genes include PTPN22 (odds ratio 1.63), involved in T-cell regulation; IL2RA (odds ratio 1.22), affecting immune response; AIRE (odds ratio 1.83), associated with autoimmune polyendocrinopathy; and PNPT1 (odds ratio 1.70), with sexually dimorphic effects.^[25] Mutations in the FUT2 gene, which influence secretor status, alter susceptibility to H. pylori infection and can worsen vitamin B12 status by impairing intrinsic factor secretion, independent of infection in some cases.^[26] Familial aggregation supports a multifactorial genetic etiology, with first-degree relatives showing a standardized incidence ratio of 3.88 for concordant pernicious anemia, rising to 6.43 among siblings.^[24] Coexisting autoimmune conditions heighten risk, as pernicious anemia frequently clusters with disorders such as type 1 diabetes, autoimmune thyroid disease, vitiligo, and Addison's disease.^[25] For instance, the familial risk for Addison's disease among pernicious anemia patients is elevated with a standardized incidence ratio of 2.45.^[24] These associations underscore a shared autoimmune predisposition.^[2]

Pathophysiology

Vitamin B12 Absorption and Deficiency

Vitamin B12, also known as cobalamin, is absorbed through a complex, multi-step process in the gastrointestinal tract. Dietary vitamin B12 is initially released from food proteins by gastric acid and pepsin in the stomach, where it binds to haptocorrin, a protective glycoprotein secreted by salivary glands and gastric mucosa.^[27] This binding shields the vitamin from degradation. In the duodenum, pancreatic proteases degrade haptocorrin in the alkaline environment, freeing vitamin B12 to bind to intrinsic factor (IF), a glycoprotein produced by parietal cells in the gastric fundus.^[28] The vitamin B12-IF complex then travels to the terminal ileum, where it is recognized and endocytosed by enterocytes via the cubam receptor complex, consisting of cubilin and amnionless proteins, in a process facilitated by calcium ions.^[27] Inside the enterocytes, vitamin B12 is released from IF and enters the portal circulation bound to transcobalamin II for delivery to tissues, primarily the liver, where stores can last 3-5 years.^[28] In pernicious anemia, an autoimmune destruction of gastric parietal cells leads to a profound deficiency of intrinsic factor, disrupting this absorption pathway. Without sufficient IF, dietary and biliary vitamin B12 cannot form the stable complex required for ileal uptake, resulting in malabsorption and eventual depletion of hepatic stores as the vitamin is lost primarily through fecal excretion.^[2] Approximately 1-2% of oral vitamin B12 can be absorbed passively via diffusion, but this is insufficient to maintain adequate levels over time, leading to progressive deficiency.^[28] Vitamin B12 deficiency progresses through distinct stages. The initial stage involves declining serum vitamin B12 levels with normal holotranscobalamin. This is followed by tissue depletion, with reduced cellular B12 levels and early biochemical abnormalities, such as elevated homocysteine and methylmalonic acid. The third stage features megaloblastic changes in the bone marrow, with impaired DNA synthesis leading to ineffective erythropoiesis, though overt anemia may not yet be present.^[29] Finally, prolonged depletion manifests as clinical symptoms, but the focus here is on the preclinical progression driven by absorption failure. As a cofactor, vitamin B12 is essential for two key enzymatic reactions. In its methylcobalamin form, it serves as a cofactor for methionine synthase, which remethylates homocysteine to methionine using 5-methyltetrahydrofolate as a methyl donor, thereby supporting DNA methylation and one-carbon metabolism.^[27] In its adenosylcobalamin form, it acts as a cofactor for methylmalonyl-CoA mutase, converting L-methylmalonyl-CoA to succinyl-CoA for entry into the citric acid cycle, preventing accumulation of toxic methylmalonic acid and supporting fatty acid and myelin synthesis.^[28] Disruption of these pathways due to deficiency underlies the metabolic derangements in pernicious anemia.

Hematological and Neurological Effects

Vitamin B12 deficiency impairs DNA synthesis in hematopoietic cells by disrupting the conversion of methyltetrahydrofolate to tetrahydrofolate, trapping folate in a metabolically inactive form and halting thymidylate production essential for nucleotide synthesis.^[30] This leads to megaloblastic erythropoiesis, characterized by enlarged, immature erythroid precursors with asynchronous nuclear and cytoplasmic maturation in the bone marrow.^[2] The resulting ineffective erythropoiesis involves intramedullary apoptosis of megaloblasts and premature cell death, contributing to reduced red blood cell production.^[30] Macrocytic anemia develops as mature erythrocytes become abnormally large (mean corpuscular volume often exceeding 100 fL), with shortened lifespan due to membrane instability and increased rigidity.^[2] Hypersegmented neutrophils, featuring more than five nuclear lobes, emerge as an early marker of this process, reflecting similar DNA synthesis defects in granulocyte precursors.^[30] Neurological effects stem from the accumulation of methylmalonic acid (MMA) due to impaired activity of the B12-dependent enzyme methylmalonyl-CoA mutase, which incorporates abnormal fatty acids into myelin, causing demyelination.^[6] This primarily affects the posterior (dorsal) and lateral columns of the spinal cord, leading to subacute combined degeneration with multifocal white matter damage and axonal loss.^[6] Elevated homocysteine, resulting from deficient methylcobalamin-dependent methionine synthase, promotes endothelial dysfunction and vascular injury, further exacerbating neuronal damage.^[31] In advanced deficiency, ineffective hematopoiesis extends to other lineages, causing pancytopenia with reductions in erythrocytes, leukocytes, and platelets.^[2] Neutropenia from this process heightens susceptibility to infections by impairing immune cell function.^[2]

Diagnosis

Clinical Evaluation

The clinical evaluation of pernicious anemia begins with a thorough history-taking to identify risk factors and symptom patterns suggestive of vitamin B12 deficiency. Clinicians should inquire about the duration and progression of fatigue, which often presents insidiously over months to years, as well as dietary habits such as strict veganism that may limit B12 intake from animal products. Additional history elements include alcohol use, which can impair B12 absorption, family history of autoimmune disorders like thyroiditis or type 1 diabetes, and prior gastrointestinal surgeries such as gastrectomy or ileal resection that disrupt intrinsic factor production or B12 uptake. Physical examination focuses on identifying characteristic signs of deficiency. Inspection for pallor of the skin and mucous membranes, mild jaundice due to ineffective erythropoiesis, and glossitis with a smooth, beefy red tongue is essential. Neurological assessment includes evaluating for deficits such as peripheral neuropathy, ataxia, or positive Romberg test indicating proprioceptive loss, while palpation checks for splenomegaly in cases of extramedullary hematopoiesis. Suspicion for pernicious anemia is heightened by red flags such as an insidious onset in older adults, particularly those over 60, presenting with combined hematological symptoms like anemia and neurological manifestations like paresthesias or cognitive changes. These features, distinct from acute presentations of other anemias, prompt further investigation into autoimmune-mediated malabsorption.

Laboratory and Confirmatory Tests

Diagnosis of pernicious anemia begins with laboratory evaluation to identify vitamin B12 deficiency and its underlying cause, typically following clinical suspicion. Initial blood tests include a complete blood count (CBC), which often reveals macrocytic anemia characterized by a mean corpuscular volume (MCV) greater than 100 fL, reduced hemoglobin levels (typically below 12 g/dL in women and 13 g/dL in men), and possible mild leukopenia or thrombocytopenia.^[2]^[17] A peripheral blood smear may show oval macrocytes, hypersegmented neutrophils (with five or more lobes), and anisopoikilocytosis, supporting the presence of megaloblastic changes.^[27]^[17] Additionally, elevated lactate dehydrogenase (LDH) levels (often >1000 U/L) and indirect bilirubin indicate ineffective erythropoiesis and intramedullary hemolysis.^[17] Specific tests for vitamin B12 status confirm deficiency. Serum vitamin B12 levels below 200 pg/mL (or 148 pmol/L) are diagnostic of deficiency, though levels between 200-300 pg/mL may require further evaluation as they can be borderline.^[2]^[27] To distinguish functional deficiency, elevated methylmalonic acid (MMA >0.4 µmol/L) and homocysteine (>13 µmol/L) levels are measured; MMA is particularly sensitive and specific for B12 deficiency, while homocysteine elevations can also occur in folate deficiency.^[2]^[27] These metabolites accumulate due to impaired B12-dependent enzymatic reactions.^[2] Confirmatory tests target the autoimmune etiology of pernicious anemia. Anti-intrinsic factor (anti-IF) antibodies are highly specific (nearly 100%), with a sensitivity of 40-70%, confirming the diagnosis when present alongside low B12 levels.^[2]^[17] Anti-parietal cell antibodies are more sensitive (up to 90% positive in affected individuals) but less specific, as they can appear in other autoimmune conditions; their presence, especially combined with anti-IF antibodies, increases diagnostic accuracy to 73% sensitivity and 100% specificity.^[2]^[17] The Schilling test, historically used to assess B12 absorption, involves oral administration of radiolabeled B12 with and without intrinsic factor; phase 1 shows reduced urinary excretion (<7% of dose) due to absorption defect, while phase 2 normalizes with added intrinsic factor, confirming pernicious anemia—though it is now obsolete due to lack of availability and ethical concerns over radioactivity.^[27]^[17] For patients with a new diagnosis, especially those ≥50 years, upper endoscopy with gastric biopsies is recommended to confirm atrophic gastritis, evaluate for gastric carcinoid or adenocarcinoma, and map the extent of mucosal involvement.^[32] In select cases, additional tests provide supportive evidence. Bone marrow aspiration and biopsy, rarely required, demonstrate hypercellular marrow with megaloblastic erythroid precursors, giant metamyelocytes, and impaired maturation.^[17] Serum gastrin levels are often elevated (>1000 pg/mL) due to reduced acid secretion from atrophic gastritis, aiding diagnosis when antibody tests are negative.^[2] Coexisting deficiencies, such as folate or iron, should be ruled out via concurrent testing to avoid masking the presentation.^[2]

Differential Diagnosis

Pernicious anemia, characterized by vitamin B12 deficiency due to autoimmune destruction of gastric parietal cells and lack of intrinsic factor, must be differentiated from other causes of B12 deficiency and similar presenting conditions to ensure accurate diagnosis.^[2] Distinguishing features include the presence of anti-intrinsic factor (anti-IF) antibodies, which are highly specific for pernicious anemia, and confirmation through laboratory tests such as elevated methylmalonic acid levels in the context of low B12.^[33] Other causes of vitamin B12 deficiency mimic pernicious anemia through impaired absorption or intake but lack the autoimmune etiology. Dietary deficiency, often seen in strict vegans or those with poor nutrition, results from inadequate B12 consumption and can be identified by a history of restricted diet without evidence of malabsorption or autoantibodies.^[2] Malabsorption syndromes, such as celiac disease or Crohn's disease affecting the terminal ileum, lead to B12 deficiency via mucosal damage; these are differentiated by endoscopy, biopsy findings, or response to gluten-free diets in celiac cases, and absence of anti-IF antibodies.^[2] Drug-induced deficiencies, for example from long-term metformin use in diabetes management, inhibit B12 absorption in the ileum and are ruled out by medication history and normalization of B12 levels upon discontinuation.^[2] Macrocytic anemias present with similar hematological findings, including elevated mean corpuscular volume, but require exclusion based on specific etiologies. Folate deficiency causes megaloblastic anemia indistinguishable on peripheral smear from B12 deficiency but is differentiated by low serum folate levels with normal B12 and absence of neurological symptoms.^[33] Alcoholism induces macrocytosis through direct bone marrow toxicity and nutritional deficits, often with concurrent liver enzyme elevations and no anti-IF antibodies.^[34] Hypothyroidism can produce mild macrocytic anemia via altered erythropoiesis, distinguished by elevated thyroid-stimulating hormone levels and response to thyroid replacement therapy.^[2] Myelodysplastic syndrome, a bone marrow disorder, may cause refractory macrocytic anemia and is confirmed by bone marrow biopsy showing dysplastic changes, unlike the reversible megaloblastosis in pernicious anemia.^[2] Neurological manifestations of pernicious anemia, such as subacute combined degeneration, overlap with other neuropathies and require careful distinction. Multiple sclerosis presents with demyelinating lesions causing sensory and motor deficits, differentiated by magnetic resonance imaging showing white matter plaques and cerebrospinal fluid oligoclonal bands.^[2] Vitamin B6 toxicity, from excessive supplementation, induces sensory neuropathy mimicking B12-related paresthesias but is identified by elevated serum B6 levels and improvement upon cessation.^[2] Diabetic neuropathy, common in uncontrolled diabetes, features distal symmetric sensory loss and is excluded by history of hyperglycemia and normal B12 levels.^[2] Key differentiators for pernicious anemia include the detection of anti-IF antibodies in 40-70% of cases, which are absent in other B12 deficiencies, and normal serum folate levels, ruling out concurrent or primary folate deficiency.^[2] Additionally, the Schilling test, though less commonly used today, historically helped confirm intrinsic factor deficiency by comparing B12 absorption with and without intrinsic factor supplementation.^[34]

Treatment and Management

Initial Therapy

The initial therapy for pernicious anemia focuses on rapid repletion of vitamin B12 stores to address the absorption defect caused by intrinsic factor deficiency, thereby correcting megaloblastic anemia and mitigating neurological risks.^[2] The standard regimen, per recent guidelines, involves intramuscular injections of cyanocobalamin or hydroxocobalamin at a dose of 1000 mcg three times per week for two weeks (or every other day if neurologic involvement is present) to achieve acute correction.^[35]^[29] This approach ensures high bioavailability, as only about 1-2% of oral doses would be absorbed in the absence of intrinsic factor.^[36] Hydroxocobalamin serves as an alternative intramuscular form, offering a longer half-life that may extend dosing intervals during the initial phase.^[2] In select cases, subcutaneous administration of cyanocobalamin (30 mcg daily for 5-10 days) or intranasal cyanocobalamin gel (500 mcg weekly) may be used, particularly for patients with needle phobia or mild deficiencies, though intramuscular remains preferred for severe presentations.^[37]^[38] Adjunctive care includes folate supplementation (1 mg daily) if concurrent deficiency is present, but only after initiating vitamin B12 to avoid masking hematological improvements while exacerbating neurological damage.^[29] For patients with severe anemia (hemoglobin <7 g/dL) and hemodynamic instability, packed red blood cell transfusion may be required, limited to 1-2 units to alleviate symptoms without precipitating fluid overload.^[36] Supportive measures for acute neurological symptoms, such as paresthesias or ataxia, involve physical therapy and pain management while awaiting B12 effects.^[2] Response to initial therapy is monitored through a rise in reticulocyte count, typically peaking within 1 week and indicating bone marrow recovery.^[29] Hematological parameters normalize within 4-8 weeks, while symptomatic improvement, including fatigue and neurological deficits, often occurs by 6 weeks, though severe neuropathy may take longer.^[2] Serial complete blood counts and serum B12 levels guide adjustments if response is suboptimal.^[36]

Long-term Management and Monitoring

Long-term management of pernicious anemia requires lifelong vitamin B12 replacement to prevent recurrence of deficiency and associated complications. The standard maintenance therapy consists of intramuscular injections of 1000 mcg hydroxocobalamin or cyanocobalamin administered monthly, following the initial treatment phase.^[2] High-dose oral vitamin B12 (1000-2000 mcg daily) is a viable alternative for maintenance, as it maintains adequate levels via passive diffusion independent of intrinsic factor.^[29]^[35]^[39] Ongoing monitoring is essential to assess treatment efficacy and screen for associated risks. Annual evaluations should include serum vitamin B12 levels, complete blood count to track hematological parameters, and neurological examinations to detect any persistent or emerging deficits such as paresthesia or ataxia.^[2] Given the underlying autoimmune atrophic gastritis, patients are at higher risk of gastric neoplasia; endoscopic surveillance with biopsies may be considered based on individual factors such as extent of atrophy or metaplasia, with intervals (e.g., every 3 years) determined by current guidelines like NICE (2024).^[35] Patient education plays a key role in ensuring adherence and early recognition of issues. Individuals must be counseled on identifying relapse symptoms, including fatigue, weakness, numbness, or cognitive impairment, to prompt timely medical evaluation. Emphasis should be placed on consistent adherence to injections or oral therapy, as non-compliance can lead to rapid symptom recurrence. While dietary absorption is impaired, patients should be advised to include B12-rich foods such as meat, fish, eggs, and fortified cereals to support general nutritional health.^[2] Comorbidities associated with pernicious anemia necessitate targeted management to optimize outcomes. Screening and treatment for coexisting autoimmune disorders, such as Hashimoto's thyroiditis or type 1 diabetes, are recommended, as they share pathogenic mechanisms with pernicious anemia. Additionally, testing for and eradicating Helicobacter pylori infection, if detected, is advised due to its higher prevalence in these patients and potential role in exacerbating gastritis.^[22]

Prognosis and Epidemiology

Prognosis

With prompt vitamin B12 replacement therapy, the hematological features of pernicious anemia, such as megaloblastic anemia and associated symptoms like fatigue and pallor, typically achieve full reversal within 1 to 2 months, with reticulocytosis often beginning within days and normalization of red blood cell counts in 4 to 6 weeks.^[2] Neurological effects, including peripheral neuropathy and subacute combined degeneration, show partial recovery if treatment is initiated early, but damage becomes increasingly irreversible if symptoms have been present for more than 6 months prior to intervention, potentially leading to persistent sensory or motor deficits.^[40]^[41] Without treatment, pernicious anemia carries a high risk of fatality, historically approaching 100% within several years due to severe anemia and complications like heart failure, though modern untreated cases still lead to significant mortality within 1 to 5 years.^[22] In contrast, with appropriate lifelong therapy, patients can expect a prognosis approaching that of the general population, with minimal excess mortality directly attributable to the condition.^[2] Patients with pernicious anemia face a 2- to 3-fold increased mortality risk from gastric adenocarcinoma, even after initiation of B12 therapy, alongside elevated risks for gastric carcinoid tumors.^[22] Persistent neurological sequelae, such as chronic neuropathy, can impair quality of life by causing ongoing pain, balance issues, or cognitive effects, particularly in cases of delayed diagnosis.^[41] Key factors influencing overall prognosis include early detection to prevent irreversible damage, adherence to maintenance B12 injections or oral supplements, and the absence of comorbidities like concurrent malignancies or autoimmune disorders.^[40]^[2]

Epidemiology

Pernicious anemia exhibits a prevalence of approximately 0.1% in the general population, rising to 1.9-2% among individuals over 60 years of age.^[42] ^[2] The annual incidence ranges from 10 to 25 cases per 100,000 individuals, predominantly affecting those over 40 years old.^[43] ^[44] These figures underscore its status as a significant yet underrecognized cause of vitamin B12 deficiency, particularly in older adults.^[45] Geographically, the condition displays notable variation, with higher prevalence observed in Northern European populations, including those in the United Kingdom and Scandinavia, where rates can reach up to 2-3% in the elderly.^[22] In contrast, prevalence is lower in populations of Asian and African descent, potentially reflecting genetic differences and underdiagnosis in developing regions due to limited access to confirmatory testing.^[2] ^[46] Demographically, pernicious anemia shows a female predominance, with a sex ratio of 1.5-2:1, and its occurrence increases markedly with age, aligning with global trends in population aging.^[22] ^[47] Studies indicate a decline in incidence in the UK from 2000-2002 to 2017-2019, potentially due to improved early detection.^[22]

History and Research

Historical Development

The earliest descriptions of pernicious anemia date back to 1822, when Scottish physician James Combe provided the first detailed portrayal of the condition, noting its severe, progressive nature characterized by profound pallor, weakness, and gastrointestinal symptoms that often led to a fatal outcome, earning it the descriptor "pernicious" due to its relentless progression.^[48] In 1855, English physician Thomas Addison offered a classic clinical account in his monograph On the Constitutional and Local Effects of Disease of the Suprarenal Capsules, emphasizing the anemia's idiopathic origins, its association with gastric atrophy, and its invariably lethal course without effective intervention, thereby establishing it as a distinct entity known as Addison's anemia.^[49] A major breakthrough occurred in 1926 when American physicians George R. Minot and William P. Murphy demonstrated that a diet rich in raw liver could dramatically reverse the symptoms of pernicious anemia in patients, inducing reticulocytosis and sustained hematologic remission; this liver therapy, building on George H. Whipple's earlier animal studies, transformed the disease from fatal to manageable and earned Minot, Murphy, and Whipple the 1934 Nobel Prize in Physiology or Medicine.^[50] In 1929, William B. Castle proposed the intrinsic factor hypothesis, suggesting that a substance in normal gastric juice (intrinsic factor) combines with an extrinsic dietary component from liver to enable vitamin absorption, explaining the gastric achylia observed in pernicious anemia patients and paving the way for targeted therapies.^[51] Mid-20th-century advances included the 1948 isolation of vitamin B12 (cobalamin) in crystalline form by Edward L. Rickes and Karl Folkers at Merck, confirming it as the anti-pernicious anemia factor and enabling the development of injectable treatments that bypassed absorption defects.^[52] The 1960s saw the identification of autoantibodies against intrinsic factor and gastric parietal cells, with key studies demonstrating their presence in patient sera, linking the condition to an autoimmune process that destroys vitamin B12-absorbing mechanisms.^[53] By the 1970s, the Schilling test—originally devised in 1953—underwent standardization for clinical use, utilizing radioactive vitamin B12 to quantify absorption and differentiate pernicious anemia from other causes of deficiency through urinary excretion measurements.^[54] In the 1980s, the autoimmune etiology gained firm recognition, with histopathological and immunological evidence solidifying pernicious anemia as a primary autoimmune disorder involving T-cell mediated destruction of gastric mucosa, often associated with other autoimmune conditions.^[55]

Current Research Directions

Recent genome-wide association studies (GWAS) have identified five risk loci for pernicious anemia, including variants near genes involved in immune regulation such as those in the IL2/IL21 region, which are implicated in autoimmune responses.^[45] These findings, derived from meta-analyses of over 2,000 cases, highlight genetic predispositions shared with other autoimmune disorders like type 1 diabetes and thyroid disease, paving the way for personalized risk screening in high-risk populations through polygenic risk scores.^[56] Diagnostic advancements focus on non-invasive methods to detect underlying atrophic gastritis, with serological panels like GastroPanel showing promise in screening asymptomatic individuals by measuring pepsinogen I/II ratios and gastrin-17 levels, achieving high specificity for autoimmune atrophic gastritis.^[57] Urea breath tests are used to detect and confirm eradication of Helicobacter pylori infection, which can contribute to or exacerbate atrophic changes in pernicious anemia contexts.^[58] Antibody assays have improved, with anti-parietal cell tests demonstrating over 90% sensitivity in confirmed cases, though specificity remains a challenge due to prevalence in healthy elderly individuals.^[59] Therapeutic research emphasizes alternatives to injections, with a 2024 systematic review confirming that high-dose oral cyanocobalamin (1,000 μg daily) effectively corrects vitamin B12 deficiency in pernicious anemia patients, leveraging passive diffusion for absorption rates sufficient in mild-to-moderate cases without intrinsic factor dependence.^[60] Intranasal cyanocobalamin formulations, such as Nascobal, are approved for maintenance therapy in pernicious anemia patients in remission, providing convenient absorption comparable to intramuscular routes.^[61] Emerging studies explore the gut microbiome's role in H. pylori-associated pernicious anemia, revealing dysbiosis patterns such as reduced microbial diversity that exacerbate atrophy and B12 malabsorption, suggesting targeted probiotics as adjuncts post-eradication.^[62] Preventive strategies target high-risk groups with autoimmune histories, recommending routine B12 monitoring and supplementation during pregnancy or in those with family predispositions to mitigate deficiency onset.^[29] Post-2021 updates to gastric cancer screening protocols advocate endoscopic surveillance every 3-5 years for pernicious anemia patients with confirmed atrophy, based on heightened adenocarcinoma risk, as outlined in recent Western guidelines.^[63] In 2024, the National Institute for Health and Care Excellence (NICE) updated guidelines on vitamin B12 deficiency, emphasizing the use of anti-intrinsic factor antibody testing for confirming pernicious anemia and recommending shared decision-making for oral versus parenteral replacement therapy, which has implications for managing pernicious anemia cases.^[35]

References

[1]
Pernicious anemia: MedlinePlus Medical Encyclopedia
### Summary of Pernicious Anemia
[2]
Pernicious Anemia - StatPearls - NCBI Bookshelf - NIH
Pernicious anemia is a relatively rare autoimmune disorder that causes diminishment in dietary vitamin B12 (cobalamin) absorption, resulting in B12 deficiency ...Etiology · Evaluation · Treatment / Management · Differential Diagnosis
[3]
Vitamin deficiency anemia - Symptoms & causes - Mayo Clinic
Sep 16, 2025 · Pernicious anemia. With this condition, the body's immune system attacks cells in the stomach that make a substance called intrinsic factor.
[4]
Pernicious Anemia Clinical Presentation - Medscape Reference
Apr 23, 2024 · The onset of pernicious anemia usually is insidious and vague. The classic triad of weakness, sore tongue, and paresthesias may be elicited ...
[5]
Spinal Cord Subacute Combined Degeneration - StatPearls - NCBI
Apr 21, 2024 · Spinal cord SCD manifests with cognitive, motor, and sensory symptoms. This condition is most commonly caused by vitamin B12 deficiency.Continuing Education Activity · Introduction · Epidemiology · History and Physical
[6]
Anemia - StatPearls - NCBI Bookshelf - NIH
Aug 8, 2023 · Myocardial infarction, angina, and high output heart failure are common complications. Other cardiac complications include the development of ...Missing: crisis | Show results with:crisis
[7]
https://www.ncbi.nlm.nih.gov/books/NBK499994/
[8]
Cancer Risk After Pernicious Anemia in the US Elderly Population
We found individuals with pernicious anemia to have significantly increased risks of gastric carcinoid tumors, adenocarcinomas, and other cancers located ...
[9]
Association pernicious anemia and autoimmune polyendocrinopathy
The association of pernicious anemia and autoimmune thyroiditis is frequent and a part of autoimmune polyglandular 3b.
[10]
Pernicious anemia, vitiligo, and infertility - PubMed
Untreated pernicious anemia has been found to be a cause of infertility. Once treated, conception often occurs within months.
[11]
Pernicious Anemia: The Hematological Presentation of a ...
Apr 17, 2022 · Pernicious anemia occurs in a later stage of autoimmune atrophic gastritis when gastric intrinsic factor deficiency and consequent vitamin B12 ...<|control11|><|separator|>
[12]
Reversal of severe osteoporosis with vitamin B12 and etidronate ...
Pernicious anemia has recently been recognized as a risk factor for osteoporosis and fractures. Although vitamin B12 is important for osteoblast function ...
[13]
Hip Fracture Risk in Patients with a Diagnosis of Pernicious Anemia
Patients with a diagnosis of PA have an elevated risk of hip fracture. The increased hip fracture risk was persistent even years after vitamin B12 therapy.
[14]
Venous thromboembolism and hyperhomocysteinemia as first ... - NIH
Sep 2, 2017 · These reports demonstrate that pernicious anemia, on its own, can lead to hyperhomocysteinemia that is significant enough to lead to thrombosis.
[15]
Pernicious anaemia: cause of recurrent cerebral venous thrombosis
May 10, 2021 · This case of recurrent cerebral venous thrombosis (CVT) highlights hyperhomocysteinemia in pernicious anemia due to vitamin B12 deficiency.
[16]
Pernicious Anemia Workup - Medscape Reference
Type I IF antibodies block binding of vitamin B12 to intrinsic factor and are found in 70% to 90% of patients with pernicious anemia. Type II IF antibodies ...
[17]
Critical influence of cytokines and immune cells in autoimmune ...
A variety of cytokines or immune cells play a central role in the process of regulating gastric parietal cells. AIG is controlled by the immune environment of ...Immune Cells · T Helper Cells · Cytokine Signalling
[18]
Update in Molecular Aspects and Diagnosis of Autoimmune Gastritis
Jun 21, 2023 · The primary autoantigen in autoimmune gastritis is H+/K+-ATPase, whose recognition by gastric T cells stimulates the secretion of Th1 cytokines.4.3. Lymphocytes And... · 5.2. Autoantibodies · 5.4. Gastrin
[19]
[PDF] Autoimmune gastritis - The Blood Project
A number of pro- inflammatory cytokines are produced by activated autoreactive T cells, amplifying the immune response and favouring parietal cell apoptosis, ...
[20]
Role of Helicobacter pylori infection in pernicious anaemia
These findings support the hypothesis that Helicobacter pylori infection could play a triggering role in a subgroup of pernicious anaemia patients.
[21]
Pernicious Anemia: Practice Essentials, Pathophysiology, Etiology
Apr 23, 2024 · Clinical onset of pernicious anemia usually is insidious and vague. The classic triad of weakness, sore tongue, and paresthesias may be elicited ...
[22]
Association of Vitamin B12 deficiency with long-term PPIs use - NIH
Proton Pump Inhibitors have been reported to cause intestinal damage and ... pernicious anemia, gastric bypass, gastrointestinal infection, ileal ...Missing: iatrogenic gastrectomy
[23]
Vitamin B12–Deficiency Anemia - NHLBI - NIH
Mar 24, 2022 · People who have pernicious anemia do not produce intrinsic factor. Pernicious anemia is more common in people with northern European or African ...
[24]
Familial Risks between Pernicious Anemia and Other Autoimmune ...
Jan 12, 2021 · Pernicious anemia (PA) is an autoimmune disease (AID) which is caused by lack of vitamin B12 (cobalamin) due to its impaired uptake.
[25]
Genome-wide association study identifies five risk loci for pernicious ...
Jun 18, 2021 · Patients with pernicious anemia have a higher incidence of other autoimmune disorders, such as type 1 diabetes, vitiligo, and autoimmune thyroid ...
[26]
Gastric intrinsic factor deficiency with combined GIF heterozygous ...
Feb 8, 2013 · We concluded that FUT2 secretor variant worsens B12 status in cases with heterozygous GIF mutations by impairing GIF secretion, independently from H. pylori- ...
[27]
Vitamin B12 Deficiency - StatPearls - NCBI Bookshelf
Vitamin B12 deficiency has 4 primary etiologies: Autoimmune: Pernicious anemia is an autoimmune condition in which antibodies to intrinsic factors are produced.Continuing Education Activity · Introduction · Etiology · Pathophysiology
[28]
Vitamin B12 | Linus Pauling Institute | Oregon State University
Treatment of pernicious anemia generally requires intramuscular injections of vitamin B12 to bypass intestinal absorption. High-dose oral supplementation may be ...
[29]
Vitamin B12 Deficiency: Recognition and Management - AAFP
Sep 15, 2017 · Vitamin B 12 deficiency is a common cause of megaloblastic anemia, various neuropsychiatric symptoms, and other clinical manifestations.
[30]
Vitamin B12 deficiency from the perspective of a practicing ...
May 11, 2017 · B 12 deficiency is the leading cause of megaloblastic anemia, and although more common in the elderly, can occur at any age.
[31]
https://pubmed.ncbi.nlm.nih.gov/23301732/
[32]
Clinical manifestations and diagnosis of vitamin B12 and folate ...
Aug 4, 2025 · Other contributing factors to anemia · Determining the underlying cause of vitamin B12 deficiency · Additional testing in pernicious anemia ...
[33]
Pernicious Anemia Differential Diagnoses - Medscape Reference
Apr 23, 2024 · Pernicious anemia must be differentiated from other disorders that interfere with the absorption and metabolism of vitamin B12 and produce cobalamin deficiency.
[34]
How I treat cobalamin (vitamin B12) deficiency - ASH Publications
Sep 15, 2008 · Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. ,. Acta Med Scand. ,. 1968. , vol. 184. (pg. 247.
[35]
vitamin B12, Athlete (cyanocobalamin) dosing, indications ...
100 mcg IM/SC once daily for 6-7 days, then every other day for 7 doses, then every 3-4 days for 2-3 weeks, then monthly.
[36]
Cyanocobalamin Nasal Gel: MedlinePlus Drug Information
May 15, 2016 · Cyanocobalamin nasal gel is used to prevent a lack of vitamin B 12 that may be caused by any of the following: pernicious anemia.
[37]
Pernicious anemia - Penn Medicine
Pernicious anemia is a decrease in red blood cells that occurs when the intestines cannot properly absorb vitamin B12.
[38]
Pernicious Anemia (Nursing) - StatPearls - NCBI Bookshelf - NIH
May 8, 2023 · Pernicious anemia is an autoimmune disorder that occurs due to autoantibodies directed against IF or gastric parietal cells (that produce IF).[1] ...Missing: definition | Show results with:definition
[39]
Optimal management of pernicious anemia - PMC - NIH
Sep 10, 2012 · Pernicious anemia (also known as Biermer's disease) is an autoimmune atrophic gastritis, predominantly of the fundus, and is responsible for a deficiency in ...
[40]
Pernicious anemia (B12 deficiency) - Evidence-Based Practice
Incidence of subclinical pernicious anemia appears higher: 1.9% of survey population had unrecognized and untreated pernicious anemia ... Morbidity/mortality.Missing: rate | Show results with:rate
[41]
Pernicious Anemia - an overview | ScienceDirect Topics
The incidence per year is roughly 25 new cases per 100,000 persons older than 40 years of age.5 Pernicious anemia most often manifests in the sixth decade or ...<|control11|><|separator|>
[42]
Genome-wide association study identifies five risk loci for pernicious ...
Jun 18, 2021 · The prevalence of pernicious anemia is around 0.1% in populations of European ancestry; however, it is more common in older people (~2% in >60 ...
[43]
Pernicious anemia: New insights from a gastroenterological point of ...
Aug 10, 2025 · PA is mainly considered a disease of the elderly, but younger patients represent about 15% of patients. PA patients may seek medical advice due ...
[44]
Pernicious Anemia: The Hematological Presentation of a ... - MDPI
Epidemiological studies have indicated that PA affects 0.1% of the general population and 2–3% of subjects aged >65 years (female:male ratio ~2:1) [3]. PA may ...Missing: geographic demographics
[45]
Milestones in the discovery of pernicious anemia and its treatment
May 9, 2023 · Pernicious anemia, an extreme form of vitamin B12-deficiency, was most likely first portrayed in 1822 by James Combe, a Scottish physician ...
[46]
Development of Knowledge Concerning the Gastric Intrinsic Factor ...
Jan 12, 2010 · Thomas Addison, 1 physician to Guy's Hospital, London, published his classic description of pernicious anemia in 1855.<|separator|>
[47]
George R. Minot – Facts - NobelPrize.org
After George Whipple showed that the formation of blood cells among dogs was stimulated by a diet rich in liver, in 1926 George Minot and William Murphy adapted ...
[48]
William B. Castle and Intrinsic Factor | Annals of Internal Medicine
Castle described the properties of intrinsic factor. By so doing, he advanced the first acceptable theory of the pathogenesis and pathophysiology of pernicious ...
[49]
Intrinsic factor antibody in serum from patients with pernicious ...
Intrinsic factor antibody in serum from patients with pernicious anaemia. Lancet. 1960 Dec 10;2(7163):1263-7. doi: 10.1016/s0140-6736(60)92461-2.
[50]
692.full.pdf - Journal of Nuclear Medicine
test by Schilling (1), a 24-hr urine collection was obtained after the oral administration of radioactive cyanocobalamin. Even very recent investigative ...
[51]
Human Autoimmunity, with Pernicious Anemia as a Model
Many investigators consider pernicious anemia an autoimmune disease. Cellular and humoral immunity to gastric antigens, particularly intrinsic factor, ...Missing: 1960s | Show results with:1960s
[52]
Genome-wide association study identifies five risk loci for pernicious ...
Jun 18, 2021 · Patients with pernicious anemia have a higher incidence of other autoimmune disorders, such as type 1 diabetes, vitiligo, and autoimmune thyroid ...
[53]
Non-invasive Screening of Autoimmune Atrophic Gastritis in ...
GastroPanel is an optimal screening tool, providing the first link in the diagnostic protocol leading to the final diagnosis of this condition.
[54]
Atrophic Gastritis Treatment & Management - Medscape Reference
Nov 27, 2024 · Eradication may be assessed by noninvasive methods, such as the urea breath test. Follow-up care may be individualized depending on the ...
[55]
Anti-gastric parietal cell antibody (GPC)
Apr 27, 2022 · Anti-gastric parietal cell antibodies are found in >90% patients with pernicious anaemia. They are not associated with duodenal ulcer or ...<|separator|>
[56]
Efficacy of different routes of vitamin B12 supplementation for the ...
Jan 17, 2024 · All IM, oral, and SL routes of administration of vitamin B12 can effectively increase the level of vitamin B12 without significant differences between them.
[57]
Pharmacokinetics of oral cyanocobalamin formulated with sodium N ...
SNAC co‐formulation produces significant enhancement of oral vitamin B12 bioavailability in rats · Medicine · 2008.Missing: intranasal | Show results with:intranasal
[58]
Alterations in the human gut microbiome associated with ... - NIH
This study reveals that certain alterations in gut microbial species and functions are associated with HPI and shows that gut microbial shift in HPI patients ...
[59]
Gastric cancer screening in Western countries: A call to action
Feb 24, 2024 · In this review, we describe primary and secondary preventive measures for gastric cancer, discussing the need to introduce screening also in Western countries.<|control11|><|separator|>